Assessment of permanent dual-chamber pacing as a treatment for drug- refractory symptomatic patients with obstructive hypertrophic cardiomyopathy: A randomized, double-blind, crossover study (M-PATHY)

Circulation

Volumn 99, Issue 22, 1999, Pages 2927-2933

  Maron, Barry J ^a   Nishimura, Rick A ^b   McKenna, William J ^c   Rakowski, Harry ^f   Josephson, Mark E ^d   Kieval, Robert S ^e  

^a MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

^b MAYO CLINIC   (United States)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e MEDTRONIC INC   (United States)

^f NONE

Author keywords

Cardiomyopathy; Hypertrophic cardiomyopathy; Pacing; Placebo; Surgery

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DISOPYRAMIDE; VERAPAMIL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; EXERCISE TOLERANCE; FEMALE; HEART MUSCLE OXYGEN CONSUMPTION; HEART VENTRICLE PACING; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0033536029     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.22.2927     Document Type: Article

References (31)

1. Maron BJ. Hypertrophic cardiomyopathy. Lancet. 1997;350:127-130.
2. Wigle ED, Rakowski H, Kimball BP, Williams WG. Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Circulation. 1995;92: 1680-1692.
3. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med. 1997;336:775-785.
4. Morrow AG, Reitz BA, Epstein SE, Henry WL, Conkle DM, Itscoitz SB, Redwood DR. Operative treatment in hypertrophic subaortic stenosis: techniques, and the results of pre and post-operative assessments in 83 patients. Circulation. 1975;52:88-102.
5. McCully RB, Nishimura RA, Tajik AJ, Schaff HZ, Danielson GK. Extent of clinical improvement after surgical treatment of hypertrophic obstructive cardiomyopathy. Circulation. 1996;94:467-471.
6. Robbins RC, Stinson EB. Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg. 1996;111:586-594.
7. McIntosh CL, Maron BJ. Current operative treatment of obstructive hypertrophic cardiomyopathy. Circulation. 1988;78:487-495.
8. Schulte HD, Bircks WH, Loesse B, Godehardt EA, Schwartzkopff B. Prognosis of patients with hypertrophic obstructive cardiomyopathy after transaortic myectomy: late results up to twenty-five years. J Thorac Cardiovasc Surg. 1993;106:709-717.
9. Heric B, Lytle BW, Miller DP, Rosenkranz ER, Lever HM, Cosgrove DM. Surgical management of hypertrophic obstructive cardiomyopathy: early and late results. J Thorac Cardiovasc Surg. 1995;110:195-208.
10. Lewis JF, Maron BJ. Clinical and morphologic expression of hypertrophic cardiomyopathy in patients ≥65 years of age. Am J Cardiol. 1994;73:1105-1111.
11. Kappenberger L, Linde C, Daubert C, McKenna W, Meisel E, Sadoul N, Chojnowska L, Guize L, Gras D, Jeanrenaud X, Rydén L. Pacing in hypertrophic obstructive cardiomyopathy. A randomized crossover study. Eur Heart J. 1997;18:1249-1256.
12. Jeanrenaud X, Goy JJ, Kappenberger L. Effects of dual-chamber pacing in hypertrophic obstructive cardiomyopathy. Lancet. 1992;339: 1318-1323.
13. Slade AKB, Sadoul N, Shapiro L, Chojnowska L, Simon J-P, Saumarez RC, Dodinot B, Camm AJ, McKenna WJ, Aliot E. DDD pacing in hypertrophic cardiomyopathy: a multicentre clinical experience. Heart. 1996;75:44-49.
14. Fananapazir L, Epstein ND, Curiel RV, Panza JA, Tripodi D, McAreavey D. Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy. Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. Circulation. 1994;90:2731-2742.
15. McDonald K, McWilliams E, O'Keefe B, Maurer B. Functional assessment of patients treated with permanent dual chamber pacing as a primary treatment for hypertrophic cardiomyopathy. Eur Heart J. 1988; 9:893-898.
16. Nishimura RA, Trusty JM, Hayes DL, Ilstrup DM, Larson DR, Hayes SN, Allison TG, Tajik AJ. Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind cross-over study. J Am Coll Cardiol. 1997;29:435-441.
17. Nishimura RA, Hayes DL, Ilstrup DM, Holmes DR Jr, Tajik AJ. Effect of dual-chamber pacing on systolic and diastolic function in patients with hypertrophic cardiomyopathy: acute Doppler echocardiographic and catheterization hemodynamic study. J Am Coll Cardiol. 1996;27:421-430.
18. Betocchi S, Losi MA, Piscione F, Boccalatte M, Pace L, Golino P, Perone-Filardi P, Briguori C, Franculli F, Pappone C, Salvatore M, Chiariello M. Effects of dual chamber pacing in hypertrophic cardiomyopathy on left ventricular outflow tract obstruction and on diastolic function. Am J Cardiol. 1996;77:498-502.
19. Maron BJ. Appraisal of dual chamber pacing therapy in hypertrophic cardiomyopathy: too soon for a rush to judgement? J Am Coll Cardiol. 1996;27:431-432.
20. Linde C, Gadler F, Kappenberger L, Rydén L. Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy. Am J Cardiol. 1999;83:903-907.
21. Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol. 1995;26: 1699-1708.
22. Panza JA, Petrone RK, Fananapazir L, Maron BJ. Utility of continuous wave Doppler echocardiography in the noninvasive assessment of left ventricular outflow tract pressure gradient in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1992;19:91-99.
23. Maron BJ, Spirito P. Implications of left ventricular remodeling in hypertrophic cardiomyopathy. Am J Cardiol. 1998;81:1339-1344.
24. Gadler F, Linde C, Juhlin-Dannfeldt A, Ribeiro A, Rydén L. Influence of right ventricular pacing site on left ventricular outflow tract obstruction in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 1996;27:1219-1224.
25. Rector TS, Kubo SH, Cohn JN. Validity of the Minnesota Living With Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo. Am J Cardiol. 1993;71:1106-1107.
26. Maron BJ, Spirito P, Green KJ, Wesley YE, Bonow RO, Arce J. Noninvasive assessment of left ventricular diastolic function by pulsed Doppler echocardiography in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1987;10:733-742.
27. Helmcke F, Nanda NC, Hsiung MC, Soto B, Adey CK, Goyal RG, Gatewood RP Jr. Color Doppler assessment of mitral regurgitation with orthogonal planes. Circulation. 1987;75:175-183.
28. Wilkoff BL, Corey J, Blackburn G. A mathematical model of the cardiac chronotropic response to exercise. J Electrophysiol. 1989;3:176-180.
29. Turner JA, Deyo RA, Loeser JD, Von Korff M, Fordyce WE. The importance of placebo effects in pain treatment and research. JAMA. 1994;271:1609-1614.
30. Posma JL, Blanksma PK, Van Der Wall EE, Vaalburg W, Crijns HJGM, Lie KI. Effects of permanent dual chamber pacing on myocardial perfusion in symptomatic hypertrophic cardiomyopathy. Heart. 1996;76: 358-362.
31. Pak PH, Maughan WL, Baughman KL, Kieval RS, Kass DA. Mechanism of acute mechanical benefit from VDD pacing in hypertrophied heart: similarity of responses in hypertrophic cardiomyopathy and hypertensive heart disease. Circulation. 1998;98:242-248.